BLEOMYCIN A6 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C60H96N20O21S2.ClH
Molecular Weight	1534.117
Optical Activity	UNSPECIFIED
Defined Stereocenters	19 / 19
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=NC(=NC(N)=C1C)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]3O)C4=CN=CN4)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCCNCCCCNCCCN

InChI

InChIKey=VBQMYJJHTWRDFG-PVRHMTBZSA-N

InChI=1S/C60H96N20O21S2.ClH/c1-25-38(77-51(80-49(25)64)30(17-36(63)84)72-18-29(62)50(65)90)55(94)79-40(46(31-19-69-24-73-31)99-59-48(44(88)42(86)34(20-81)98-59)100-58-45(89)47(101-60(66)96)43(87)35(21-82)97-58)56(95)74-27(3)41(85)26(2)52(91)78-39(28(4)83)54(93)71-16-9-37-75-33(23-102-37)57-76-32(22-103-57)53(92)70-15-8-14-68-12-6-5-11-67-13-7-10-61;/h19,22-24,26-30,34-35,39-48,58-59,67-68,72,81-83,85-89H,5-18,20-21,61-62H2,1-4H3,(H2,63,84)(H2,65,90)(H2,66,96)(H,69,73)(H,70,92)(H,71,93)(H,74,95)(H,78,91)(H,79,94)(H2,64,77,80);1H/t26-,27+,28+,29-,30-,34-,35+,39-,40-,41-,42+,43+,44-,45-,46-,47-,48-,58+,59-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C60H96N20O21S2
Molecular Weight	1497.656
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	19 / 19
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12567444 | https://adisinsight.springer.com/drugs/800009288 | https://www.ncbi.nlm.nih.gov/pubmed/26460847

Bleomycin A6 (also known as boanmycin) was developed in China as an antineoplastic antibiotic. This drug participated in clinical trials for the treatment of Squamous Cell Lung Cancer. It was shown that besides the antitumor effect, Bleomycin A6 had the ability to alter the tumor microenvironment and could contribute toward lung cancer relapse and metastasis on long-term treatment. The development of this drug, apparently, was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
Bleomycin A6-loaded anionic liposomes with in situ gel as a new antitumoral drug delivery system.	2016	24845479
[Inhibitory effect of bleomycin A6 on human colon cancer xenografts in nude mice].	1990-10	1714798
[Preclinical pharmacologic evaluation of bleomycin A6].	1989-07	2483136

Sample Use Guides

In Vivo Use Guide

Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Wed Apr 02 10:11:11 GMT 2025` Edited by `admin` on `Wed Apr 02 10:11:11 GMT 2025`
Record UNII	K4QGS58U92
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Bleomycin A6 hydrochloride [WHO-DD]

Preferred Name

English

BLEOMYCIN A6 HYDROCHLORIDE

Common Name

English

N1-(3-((4-((3-AMINOPROPYL)AMINO)BUTYL)AMINO)PROPYL)BLEOMYCINAMIDE HYDROCHLORIDE

Systematic Name

English

BLEOMYCINAMIDE, N1-(3-((4-((3-AMINOPROPYL)AMINO)BUTYL)AMINO)PROPYL)-, HYDROCHLORIDE

Systematic Name

English

Code System Code Type Description

CAS

1187436-74-3